Explore tweets tagged as #CM8HW
Day 1 #ASCO25 highlights: . 1. Review on recent approvals . 2. #BREAKWATER (update): BRAF+ mCRC. 3. #CM8HW (update): MSI-H mCRC. 4. #DYNAMIC: ctDNA in colon ca. 5. #CAIRO6: periOP Rx in peritoneal mets . #OncTwitter @ASCO . 1/6
3
77
228
#GI25 highlights #CommunityOnc:. 1. #SCIENCE: Adv Eso SCC . 2. #ESOPEC publication (Eso/GEJ/Ga). 3. Chemo in resectable Panc Ca. 4. #StarterNET: GEP-NET . 5. #CM8HW: dMMR/MSI-H mCRC . 6. #BREAKWATER: BRAFV600E mCRC. 7. ctDNA: #BESPOKE + SWOG80702 . #OncTwitter #gism @ASCO . 1/8
4
83
226
Day 3 #GI24 @ASCO Highlights #CommunityOncology. 1. #ctDNA:.- #BESPOKE.- #GALAXY.- #COBRA . 2. #CM8HW: ICI in MSI-H/dMMR 1L CRC. 3. #SuppOnc: #Sexualhealth #QoL #PatientReportedOutcomes . #OncEd #MedEd #OncTwitter #MedTwitter #gism #crcsm . 1/4
1
30
79
#GI24 @ASCO Highlights w/ @PamelaKunzMD . - #CM8HW .- #EMERALD1.- #NETTER2.- #BESPOKE #GALAXY . Full discussion: .- - - Also on the “Oncology Brothers” podcast. #MedTwitter #OncTwitter #gism @TargetedOnc #MedEd #OncEd
2
10
32
CM8HW: nivo/ipi vs CT in 1st line dMMR mCRC update.- in centrally confirmed dMMR/MSI-H: Nivo+Ipi (n=171) vs CT (n=84). - Median FU 31.5mo: superior PFS with nivo/ipi; HR 0.21!!! 🙌.- PFS2 NR vs 30mo for CTx, HR 0.27.- 2 TR deaths in nivo/ipi arm.#ASCO24
0
20
42
Excellent discussion (as always) of CM8HW by @ChiaraCrem1 . Cross-trial comparisons: “don’t do this at home. But we do it anyway.” #ESMOGI24 @myESMO #ESMOambassadors
3
12
43
First results of the CM8HW are out! Nivo/ipi vs chemo in 1st line dMMR mCRC. We knew it would be positive, but wow 🤯 HR 0.21 for PFS and + across all subgroups. No crossing of the curves! Toxicity very manageable (don’t be scared of low dose ipi1).
15
134
343
Long awaited practice-changing results from ph 3 CM8HW now out in @TheLancet. Nivo/ipi sign better than nivo mono in dMMR mCRC.@sara_lonardi1 @bmsnews #GI25 .
4
38
125
@ASCO #ASCO24 #CRCsm .Great discussion dMMR CRC @KristenCiombor .👉CM8HW - impressive HR 0.21 but awaiting nivo vs nivo-ipi 🐘.👉NEOPRISM-CRC, neoadjuvant dual IO 🇨🇳 - not yet ready for prime-time.Thank you for these great summary tables! 🙌 .@OncoAlert
0
5
20
@sara_lonardi1 presenting QoL data from CM8HW study of 1st line nivo/ipi vs chemo in prs with dMMR mCRC💪!.#ESMOambassadors #ESMOGI24 @myESMO
0
3
6
Had a great time discussing #CM8HW with the @OncBrothers last week. A major step forward for our dMMR CRC patients!.
Ipi + Nivo is now approved in dMMR/MSI-H mCRC based off #CM8HW! Before #ASCO25, we had a chance to 🗣️ this trial, findings, dosing, single vs. dual ICI and AEs w/ @GIMedOnc . Full 🗣️:.⭐️ ⭐️ Also on “Oncology Brothers” podcast . #OncTwitter #gism #GiOnc
2
7
31
Patients w/ MSI-H #coloncancer with liver metastases derive benefit with dual checkpoint #immunotherapy —much different than in MSS and other GI cancers —described in CM8HW and in poster of updated result of Checkmate 142. #GI24
0
8
14
Great discussion on #CM8HW Ipi+Nivo in unresectable/advanced dMMR/MSI-H colorectal cancer by @GIMedOnc and @OncBrothers 👏🏻 .Must watch 👇 . Ipi+Nivo is a new SOC option for these patients. Single-agent IO still remains a standard option for more frail patients or others where.
Ipi + Nivo is now approved in dMMR/MSI-H mCRC based off #CM8HW! Before #ASCO25, we had a chance to 🗣️ this trial, findings, dosing, single vs. dual ICI and AEs w/ @GIMedOnc . Full 🗣️:.⭐️ ⭐️ Also on “Oncology Brothers” podcast . #OncTwitter #gism #GiOnc
0
1
9
Nice to see CM8HW in press! @NEJM .📌 n=303 centrally confirmed dMMR mCRC 1L.➡️ 2y PFS 72% nivo-ipi vs 14% chemo 🌟 .Per earlier BMS release, combo is superior to nivo arm but awaiting data - in whom? by how much? toxicity diff?.❓How do we identify pts w/dMMR mCRC who may still
The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results:
0
23
44
2. #CM8HW: Ipi/Nivo vs Nivo vs Chemo in 1L for mCRC w/ MSI-H/dMMR. - mPFS significantly improved with ICI. At 24 mos, 72% w/ Ipi/Nivo vs 14% w/ chemo. HR: 0.21.- Eagerly waiting to see Nivo alone data.- Different AESs w/ ICI and less Gr 3 toxicities BUT 2 mortalities associate w/
First results of the CM8HW are out! Nivo/ipi vs chemo in 1st line dMMR mCRC. We knew it would be positive, but wow 🤯 HR 0.21 for PFS and + across all subgroups. No crossing of the curves! Toxicity very manageable (don’t be scared of low dose ipi1).
2
3
13
